• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2022 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • SOP Web STAT
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

DrugDiscovery @LPBI Group

© 2016

“DrugDiscovery @LPBI Group”

is a Start Up in

Health/Life Sciences in MA

“DrugDiscovery @LPBI Group” combines expertise from three sources:

a.   Leadership of SBH Sciences, Inc, CEO, Raphael Nir, PhD

        Co-Founder: “DrugDiscovery @LPBI Group”, Expertise for Startup evolution:

  • Management: Team building, Funding, Decision Making
  • All Aspects of R&D Management
  • Conceptual Leadership

b.   Leadership of LPBI Group, Founder, Aviva Lev-Ari, PhD, RN

       Co-Founder: “DrugDiscovery @LPBI Group”, Expertise for Startup evolution:

  • Management: Team building, Funding, Administration
  • R&D Management: Concept Design Strategy, Combination Drug Therapy

       Co-Founder “DrugDiscovery @LPBI Group”, Stephen J. Williams, PhD,                          Expertise for Startup evolution:

  • Strategic Decision Making
  • All Aspects of Research
  • Conceptual Leadership in Drug Formulation
  • 3D BioPrinting: Drug Dosing and Printing

c.   Team members of LPBI Group, M3DP Venture (Subsidiary #3)

c.1 Member of Technical Staff: Tilda Barliya, PhD, Expertise for Startup evolution:

  • All Aspects of Research
  • Conceptual Leadership in Drug Formulation, nano beads, oncology, genomics

c.2 Member of Technical Staff: Irina Robu, PhD, Expertise for Startup evolution:

  • All Aspects of Research related to Material Science, Tissue Engineering
  • Conceptual Leadership in Drug-Device design for drug delivery, Smart Polymers

c.3 Member of Technical Staff: David Orchard-Webb, Expertise for Startup evolution

  • cancer biology, pancreatic disorders, biologics, molecular and cellular biology and immunology
  • Conceptual Leadership in Novel mechanism of action and combination therapy of Biologics

We are adding Scientists to our Team

 

SBH Sciences, Inc. & LPBI Group’s M3DP, Subsidiary #3

Thrusts of  “DrugDiscovery @LPBI Group” include:

  1. Drug Discovery with 3D BioPrinting
  2. Drug Delivery System – One solution for many agents for many indications
  3. Stem Cell Reprogramming & Gene Therapy
  4. Gene Editing for Gene Therapies with 3D BioPrinting
  5. JVIP – TEAM PRESENTATIONS 1/4/2016 – 3/31/2016

Drug Development – Three Indications

  • Diabetes – A Combination Drug Therapy to induce Insulin Production by Pancreatic Beta Cells (PPAR-gamma, Leptin, ..)
  • Inflammatory Disorders: Inflammatory Bowel Diseases (IBD) – Crohn’s and Ulcerative Colitis (UC) and Others
  • Anti-Cancer Drug Discovery @ LPBI Group’s Research Biotech Businesses

Methodology and Processes

  • CRISPR – genecards.org, UCSC, NM/OK, Caribou BioSciences
  • PROTOCOL for LPBI Group’s Recruiting Strategy for R&D Scientists I,II,III and R&D Project Managers for Drug Discovery: Three Indications Considered
  • PROTOCOL for Drug Screening of 3rd Party Intellectual Property Presented for Funding Representation

The Team

Team Profile: DrugDiscovery @LPBI Group – A BioTech Start Up submitted for Funding Competition to MassChallenge Boston 2016 Accelerator

https://accelerate.masschallenge.org/startup/11021/team/

We are Applicants for MassChallenge Boston 2016 Accelerator

https://accelerate.masschallenge.org/startup/11021/team/

 

From: MassChallenge <apply@masschallenge.org>

Date: Monday, March 28, 2016 at 1:11 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Cc: MassChallenge <apply@masschallenge.org>

Subject: Your MassChallenge 2016 Jun-Oct Program Cycle Application for DrugDiscovery@LPBI Group has been Submitted

Hi Aviva,

Thank you for submitting your application for MassChallenge Boston 2016 Accelerator for your startup, DrugDiscovery@LPBI Group. It has been received and will be reviewed by MassChallenge judges.

Best,

The MassChallenge Team

++

From: MassChallenge <contact@masschallenge.org>

Reply-To: <contact@masschallenge.org>

Date: Saturday, April 2, 2016 at 3:17 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: MC Update – Applications Close 

Boston, Jerusalem Lausanne – Timeline

February 9: Applications Open. Entrepreneurs apply online to MassChallenge 2016 programs.

March 2 (NOON EST): Early bird application deadline. Apply early and receive discounted application fee ($49).

April 1 (NOON EDT): Regular application deadline. This is the last date to submit applications for the 2016 accelerator programs. Regular application fee applies ($99).

March 29 – April 22: Round 1 Judging: Expert judges assess online applications and provide feedback to entrants. Each application receives scoring and feedback from multiple judges.  

May 4 – May 11: Round 2 Judging: Semi-finalist startups deliver 20-minute pitches to panels of judges in Boston, Lausanne, or Jerusalem. Live Q&A followed up by written scoring and feedback. 

May 19: Finalist Announcement. The most promising startups are invited to participate in the MassChallenge 2016 accelerator programs as finalists.

June 20 – October 14: Accelerator Program. Access to world-class mentorship, training, office space, funding, marketing, media and other resources. 

September 27 – September 29: Pre-final Judging: Finalists pitch to panels of judges highlighting their progress during the accelerator.

October 13 & 14: Final Judging. The top 26 startups pitch to high profile judges, who determine cash awards.

October 27: Israel Awards Ceremony. 

November 2: Boston Awards Ceremony. 

Click to Browse the 2016 Startup Applicants

About LPBI Group

Lines of Business #1,2,3,4,5 are in

  • eScientific Digital Media & IP Asset Management (Subsidiary #1 and #4)

and in

  • Funding Early Stage (Subsidiary #2)

http://pharmaceuticalintelligence.com/gama-delta-epsilon-gde-is-a-global-holding-company-absorbing-lpbi/ 

About “DrugDiscovery @LPBI Group”

“DrugDiscovery @LPBI Group” is assuming the activities of Subsidiary #5: SBH Sciences, Inc and LPBI Group’s Team in Biotech 3D BioPrinting R&D – Drug Development (Subsidiary #3: M3DP: Team in Drug Development and Team in Medical Devices)

  • Subsidiary 3: Medical 3D BioPrinting – M3DP
  • Subsidiary 5: Joint Ventures for IP Development – JVIP

We are in Research Biotech Businesses

  • Subsidiary 3: R&D in 3D BioPrinting

Line-of-Business #6: “3D BioPrinting: Drugs” & “3DBioPrinting: Medical Devices”

Tissue Engineering, Gene Therapy: Stem Cells & Gene Editing, Medical Devices: Product Concepts

&

  • Subsidiary 5: Pharmaceutical R&D: Drug Discovery and Drug-Devices Development

Line-of-Business #7:

  • Drug Discovery with 3D BioPrinting

Line-of-Business #8:

  • Drug Delivery System – One solution for many agents for many indications

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to print (Opens in new window)
  • Click to email a link to a friend (Opens in new window)

Like this:

Like Loading...

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 1,254 other subscribers
  • Recent Posts

    • Press Release for Five Bilingual BioMed e-Series January 29, 2023
    • 2022 FDA Drug Approval List, 2022 Biological Approvals and Approved Cellular and Gene Therapy Products January 17, 2023
    • Verily announced other organizational changes, 1/13/2023 January 16, 2023
    • Mission 4: Use of Systems Biology for Design of inhibitor of Galectins as Cancer Therapeutic – Strategy and Software December 13, 2022
    • Science Has A Systemic Problem, Not an Innovation Problem December 12, 2022
    • Chemistry Nobelist Carolyn Bertozzi’s years at UC Berkeley October 24, 2022
    • Technion #1 in Europe in Field of AI for 2nd Straight Year October 20, 2022
    • Endoglin Protein Interactome Profiling Identifies TRIM21 and Galectin-3 as New Binding Partners October 11, 2022
    • The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells October 11, 2022
    • Cancer Policy Related News from Washington DC and New NCI Appointments October 4, 2022
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 Amandeep Kaur
    • 1 Aashir Awan, Phd
    • 1 Abhisar Anand
    • 1 Adina Hazan
    • 1 Alan F. Kaul, PharmD., MS, MBA, FCCP
    • 1 alexcrystal6
    • 1 anamikasarkar
    • 1 apreconasia
    • 1 aviralvatsa
    • 1 David Orchard-Webb, PhD
    • 1 danutdaagmailcom
    • 1 Demet Sag, Ph.D., CRA, GCP
    • 1 Dror Nir
    • 1 dsmolyar
    • 1 Ethan Coomber
    • 1 evelinacohn
    • 1 Gail S Thornton
    • 1 Irina Robu
    • 1 jayzmit48
    • 1 jdpmd
    • 1 jshertok
    • 1 kellyperlman
    • 1 Ed Kislauskis
    • 1 larryhbern
    • 1 Madison Davis
    • 1 marzankhan
    • 1 megbaker58
    • 1 ofermar2020
    • 1 Dr. Pati
    • 1 pkandala
    • 1 ritusaxena
    • 1 Rick Mandahl
    • 1 sjwilliamspa
    • 1 Srinivas Sriram
    • 1 stuartlpbi
    • 1 Dr. Sudipta Saha
    • 1 tildabarliya
    • 1 vaishnavee24
    • 1 zraviv06
    • 1 zs22

Powered by WordPress.com.

WPThemes.


%d bloggers like this: